Skip to main content
Premium Trial:

Request an Annual Quote

Sirna Exclusively Licenses UMMS Zamore miRNA Patents

NEW YORK, May 10 (GenomeWeb News) - Sirna Therapeutics said today that it has taken an exclusive worldwide license for miRNA technology from the University of Massachusetts Medical School.


According to Sirna, the patents cover microRNA technology for the modulation of gene expression, and could strengthen its IP position in the miRNA market. The license is for all uses, including therapeutics, diagnostics, and research reagents, Sirna said.


The patents cover technology invented by UMMS scientists Phillip Zamore and Gyorgy Hutvagner, and provides methods for inhibiting small RNA function, such as microRNA function in vitro and in vivo, Sirna said. The company maintained that the patents "describe methods that can be used not only for advancing RNAi basic research, but also for developing miRNA-based therapeutics. "


The financial terms of the license were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.